Knockdown of c-FLIPL enhanced AD5-10 anti-death receptor 5 monoclonal antibody-induced apoptosis in human lung cancer cells

Cancer Science

Volumn 100, Issue 5, 2009, Pages 940-947

  Chen, Feng ^a   Guo, Juntang ^b   Zhang, Yaxi ^a   Zhao, Yu ^c   Zhou, Naikang ^b   Liu, Shilian ^a   Liu, Yanxin ^a   Zheng, Dexian ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYTOCHROME C; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AD5 10; PROTEIN BCL XL; PROTEIN BID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FAMILY;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 65349102222     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01119.x     Document Type: Article

References (33)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001; 51: 15-36.
2. Ferreira CG, Huisman C, Giaccone G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2002; 41: 57-77.
3. Carlo-Stella C, Lavazza C, Locatelli A, Vigano L, Gianni AM, Gianni L. Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res 2007; 13: 2313-7.
4. Walczak H, Miller RE, Ariail K et al. Tumoricidal activity of tumor necrosis factor-related apoptos-inducing ligand in vivo. Nat Med 1999; 5: 157-63.
5. Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007; 251: 146-57.
6. Jo M, Kim TH, Seol DW et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor related apoptosis-inducing ligand. Nat Med 2000; 6: 564-7.
7. Lawrence D, Shahrokh Z, Marsters S et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-5.
8. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
9. Guo Y, Chen C, Zheng Y et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 2005; 280: 41 940-52.
10. Shi J, Liu Y, Zheng Y et al. Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice. Cancer Res 2006; 66: 11 946-53.
11. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor 1 and CD95 induced apoptosis. J Biol Chem 1997; 272: 17 255-7.
12. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN. c-FLIP R, a new regulator of death receptor-induced apoptosis. J Biol Chem 2005; 280: 14 507-13.
13. Yeh WC, Itie A, Elia AJ et al. Requirement for casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000; 12: 633-42.
14. Chaudhary PM, Eby MT, Jasmin A, Kumar A, Liu L, Hood L. Activation of the NF-κ B pathway by caspase 8 and its homologs. Oncogene 2000; 19: 4451-60.
15. Kataoka T, Budd RC, Holler N et al. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr Biol 2000; 10: 640-8.
16. Shu HB, Halpin DR, Goeddel DV. Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 1997; 6: 751-63.
17. Shi J, Zhang J, Chang X, Liu S, Liu Y, Zheng D. Expression and biological activity of the soluble recombinant tumor necrosis factor related apoptosis inducing ligand. Chin J Bioengineering 2003; 23: 46-9.
18. Shi J, Zheng D, Liu Y et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005; 65: 1687-92.
19. Flahaut M, Mühlethaler-Mottet A, Auderset K et al. Persistent inhibition of FLIP (L) expression by lentiviral small hairpin RNA delivery restores death-receptor-induced apoptosis in neuroblastoma cells. Apoptosis 2006; 11: 255-63.
20. Longley DB, Wilson TR, McEwan M et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25: 838-48.
21. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-5.
22. Buchsbaum DJ, Zhou T, Grizzle WE et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003; 9: 3731-41.
23. Chuntharapai A, Dodge K, Grimmer K et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001; 166: 4891-8.
24. Ichikawa K, Liu W, Zhao L et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Med 2001; 7: 954-60.
25. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE. Induction of tumor-specific T cell immunity by anti-DR5 antibody. Ther J Exp Med 2004; 199: 437-48.
26. Koornstra JJ, Kleibeuker JH, van Geelen CM et al. Expression of TRAIL (TNF-related apoptosis inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003; 200: 327-35.
27. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand mediated caspase-8 activation and apoptosis. Cancer Res 2001; 6: 1645-51.
28. Mongkolsapaya J, Cowper AE, Xu XN et al. Lymphocyte inhibitor of TRAIL (TNF related apoptosis-inducing ligand): A new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol 1998; 160: 3-6.
29. Yamaguchi Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y. Adenovirus-mediated transfection of caspase-8 sensitizes hepatocellular carcinoma to TRAIL- and chemotherapeutic agent-induced cell death. Biochim Biophys Acta 2006; 1763: 844-53.
30. Straughn JM Jr, Oliver PG, Zhou T et al. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 2006; 101: 46-54.
31. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000; 60: 4122-9.
32. Zhou XD, Yu JP, Liu J, Luo HS, Chen HX, Yu HG. Overexpression of cellular FLICE-inhibitory protein (FLIP) in gastric adenocarcinoma. Clin Sci (London) 2004; 106: 397-405.
33. Horak P, Pils D, Kaider A et al. Perturbation of the tumor necrosis factor related apoptosis-inducing ligand cascade in ovarian cancer. overexpression of FLIP L and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res 2005; 11: 8585-91.